{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:36Z","timestamp":1791993936953,"version":"4.4.0"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Nephropathy is a major Fabry disease complication. Kidney biopsies reveal glomerulosclerosis even in pediatric patients. The main manifestations of Fabry nephropathy include reduced glomerular filtration rate and proteinuria. In 2016, an oral pharmacological Chaperone was approved to treat Fabry patients with \u201camenable\u201d mutations. Because (i) Fabry disease is a rare disorder that frequently causes kidney damage, and (ii) a new therapeutic is currently available, it is necessary to review wich biomarkers are useful for nephropathy follow-up among Fabry \u201camenable\u201d patients receiving migalastat. The literature search was conducted in MEDLINE, EMBASE, SCOPUS, Cochrane, and Google academic. Prospective studies in which renal biomarkers were the dependent variable or criterion, with at least 6 months of follow-up, were included. Finally, we recorded relevant information in an ad hoc database and summarized the main results. To date, the main useful biomarker for nephropathy monitoring among Fabry \u201camenable\u201d patients receiving migalastat is glomerular filtration rate estimated by equations that include serum creatinine.<\/jats:p>","DOI":"10.3390\/genes13101751","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T20:58:47Z","timestamp":1664398727000},"page":"1751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1462-2703","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Jaurretche","sequence":"first","affiliation":[{"name":"Renal and Pancreas Transplant Department, Sanatorio Parque de Rosario, Rosario S2000, Argentina"},{"name":"Biophysics and Human Physiology, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Conde","sequence":"additional","affiliation":[{"name":"Biophysics and Human Physiology, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonzalez Schain","sequence":"additional","affiliation":[{"name":"Biophysics and Human Physiology, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-0793","authenticated-orcid":false,"given":"Franco","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Biophysics and Human Physiology, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Sgro","sequence":"additional","affiliation":[{"name":"Biophysics and Human Physiology, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Venera","sequence":"additional","affiliation":[{"name":"Biophysics and Human Physiology, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"},{"name":"Research Department, School of Medicine, Instituto Universitario Italiano de Rosario, Santa Fe S2000CTT, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgmr.2017.05.007","article-title":"Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina","volume":"12","author":"Jaurretche","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Bostad","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00467-018-4006-3","article-title":"Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: Is a correlation possible?","volume":"33","author":"Politei","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_7","first-page":"9543079","article-title":"Early renal involvement in a girl with classic Fabry disease","volume":"2017","author":"Perretta","year":"2017","journal-title":"Case Rep. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: A review\u2013how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of \u03b1-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"ref_10","first-page":"101","article-title":"Vascular disease in male patients with fabry disease on hemodialysis: A retrospective cohort study in Argentina","volume":"39","author":"Jaurretche","year":"2019","journal-title":"Rev. Nefrol. Dial. Traspl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a mutant \u03b1-galactosidase gene product for the late-onset cardiac form of Fabry disease","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Weidemann, F., Jovanovic, A., Herrmann, K., and Vardarli, I. (2022). Chaperone Therapy in Fabry Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031887"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nbt1018-913","article-title":"FDA approves Galafold, a triumph for Amicus","volume":"36","author":"Moran","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_16","unstructured":"FDA-NIH Biomarker Working Group (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource."},{"key":"ref_17","first-page":"51","article-title":"Pharmacological chaperones. New therapeutic alternative for Fabry disease nephropaty in Argentina","volume":"40","author":"Jaurretche","year":"2020","journal-title":"Rev. Nefrol. Dial. Traspl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","article-title":"Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study","volume":"131","author":"Hughes","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","article-title":"Treatment of Fabry Disease management with migalastat\u2014outcome from a prospective 24 months observational multicenter study (FAMOUS)","volume":"8","author":"Lenders","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: Real-life data","volume":"28","author":"Riccio","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating Fabry disease: Enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"Gensler","year":"2019","journal-title":"Clin. Pharm. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","article-title":"Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment","volume":"54","author":"Mauer","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","article-title":"Treatment of Fabry\u2019s disease with migalastat: Outcome from a prospective observational multicenter study (FAMOUS)","volume":"108","author":"Lenders","year":"2020","journal-title":"Clin. Pharm. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: Data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ajmg.a.61105","article-title":"Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study","volume":"179","author":"Hughes","year":"2019","journal-title":"Am. J. Med. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ndt\/gfy104.SP004","article-title":"SP004 effects of long-term migalastat treatment on renal function by baseline proteinuria in patients (PTS) with fabry disease","volume":"33","author":"Schiffmann","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","unstructured":"Mignani, R., and Dialisi, U.N. (2019). The Fabry nephropathy: New insight in diagnosis, monitoring and treatment. G. Ital. Nefrol., 36."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10157-013-0897-2","article-title":"Fabry disease: Experience of screening dialysis patients for Fabry disease","volume":"18","author":"Kusano","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10157-019-01810-w","article-title":"Efficacy and safety of migalastat in a Japanese population: A subgroup analysis of the ATTRACT study","volume":"24","author":"Narita","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Di Stefano, V., Mancarella, M., Camporeale, A., Regalia, A., Ferraresi, M., Pisaniello, M., Cassinerio, E., Pieruzzi, F., and Motta, I. (2021). Migalastat treatment in a kidney-transplanted patient with fabry disease and n215s mutation: The first case report. Pharmaceuticals, 14.","DOI":"10.3390\/ph14121304"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1049-8","article-title":"Increased urinary CD80 excretion and podocyturia in Fabry disease","volume":"14","author":"Trimarchi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_35","first-page":"4027606","article-title":"Variables associated with a urinary MicroRNAs excretion profile indicative of renal fibrosis in Fabry disease patients","volume":"2019","author":"Jaurretche","year":"2019","journal-title":"Int. J. Chronic Dis."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/10\/1751\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:40:57Z","timestamp":1760143257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/10\/1751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["genes13101751"],"URL":"https:\/\/doi.org\/10.3390\/genes13101751","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}